Fidelity Investments’s Rapport Therapeutics RAPP Stock Holding History

Fidelity Investments’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$299M	Buy	7,172,894 +3,955	+0.1%	+$145K	0.01%	755
2026 Q1	$224M	Buy	7,168,939 +57,074	+0.8%	+$1.61M	0.01%	798
2025 Q4	$216M	Buy	7,111,865 +194,870	+3%	+$5.39M	0.01%	842
2025 Q3	$205M	Buy	6,916,995 +1,442,362	+26%	+$25.7M	0.01%	831
2025 Q2	$62.2M	Sell	5,474,633 -11,835	-0.2%	-$126K	﹤0.01%	1307
2025 Q1	$55M	Hold	5,486,468	–	–	﹤0.01%	1319
2024 Q4	$97.3M	Hold	5,486,468	–	–	0.01%	1134
2024 Q3	$112M	Buy	5,486,468 +503,117	+10%	+$10.8M	0.01%	1056
2024 Q2	$116M	Buy	+4,983,351	New	+$115M	0.01%	995

Other funds holding RAPP

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments's RAPP Position: Q2 2026 in Review

Fidelity Investments increased its Rapport Therapeutics (RAPP) stake by 0.06% in Q2 2026, buying an estimated $145K and bringing the position to 7,172,894 shares worth $299M. The position accounts for 0.01% of the portfolio, ranked #755.

Fidelity Investments first reported a position in RAPP in Q2 2024 and has held it in 9 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

Fidelity Investments held 7,172,894 shares of Rapport Therapeutics worth $299M as of Q2 2026.
Fidelity Investments bought 3,955 Rapport Therapeutics shares in Q2 2026, an estimated $145K.
Rapport Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q2 2026, its #755 holding.
Fidelity Investments first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 9 quarters since.
161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.